Does in vivo ventricular gene delivery of Adeno-betaARKct reverse ventricular dysfunction in the infarcted/failing post-MI heart?
In vivo gene delivery of a βARK1 inhibitor (Adeno-betaARKct) reverses ventricular dysfunction in the post-MI failing heart, suggesting a novel therapeutic strategy.
In vivo delivery of Adeno-betaARKct is feasible in the infarcted/failing heart by coronary catheterization; expression of betaARKct results in marked reversal of ventricular dysfunction. Thus, inhibition of betaARK1 provides a novel treatment strategy for improving the cardiac performance of the post-MI heart.
Shah et al. (Tue,) studied this question.